Nov 5, 4:09 PM ET
Globus Medical reported third quarter 2026 worldwide net sales of $763.7 million, representing a 0.7% decrease compared to the same period in 2025, alongside GAAP net income of $141.2 million. The company updated its full-year 2026 revenue guidance to $3.09 billion and announced a $500 million increase to its share repurchase program.
- Worldwide net sales were $763.7 million for the third quarter ended September 30, 2026, down 0.7% year-over-year.
- GAAP diluted earnings per share increased 18.2% to $1.04 for the quarter.
- The Board authorized an additional $500.0 million share repurchase program increase on November 2, 2026.
- Full-year 2026 revenue guidance was updated to $3.09 billion.
Read the filing on SEC.gov ↗
Aug 6, 4:19 PM ET
Globus Medical reported second-quarter 2026 worldwide net sales of $789.6 million, up 5.9%, and raised its full-year 2026 non-GAAP diluted EPS guidance to $4.95 to $5.05 from $4.70 to $4.80. GAAP diluted EPS fell 26.2% to $1.10, mainly because of a $110.5 million bargain purchase gain recorded in the prior-year quarter related to the Nevro acquisition. Full-year 2026 revenue guidance of $3.18 billion to $3.22 billion was reaffirmed.
- Q2 2026 worldwide net sales were $789.6 million, up 5.9% as reported and 5.6% on a constant currency basis.
- Non-GAAP diluted EPS was $1.34, up 55.8% from $0.86; GAAP diluted EPS was $1.10, down 26.2% from $1.49.
- Full-year 2026 non-GAAP diluted EPS guidance raised to $4.95 to $5.05 from $4.70 to $4.80.
- Full-year 2026 revenue guidance reaffirmed at $3.18 billion to $3.22 billion.
Read the filing on SEC.gov ↗
Jun 4, 4:11 PM ET
At its June 3, 2026 annual meeting, Globus Medical stockholders approved an amendment raising the shares authorized under its 2021 Equity Incentive Plan by 1,000,000, to 12,000,000 Class A shares. Stockholders also re-elected director Keith W. Pfeil and elected Robert A. Douglas to Class II terms, ratified Deloitte & Touche LLP as auditor for 2026, and approved executive compensation on an advisory basis.
- Equity plan amendment: 246,228,534 for, 75,266,538 against, 79,135 abstain, 6,902,949 broker non-votes
- Total shares authorized under the plan rise to 12,000,000 from 11,000,000 for incentive stock options, which are now 12,000,000
- Director votes: Keith W. Pfeil 293,453,432 for and 28,120,775 withheld; Robert A. Douglas 311,683,904 for and 9,890,303 withheld
- Deloitte & Touche LLP ratified for fiscal year ending December 31, 2026, with 327,965,803 for and 467,955 against
Read the filing on SEC.gov ↗
May 7, 4:20 PM ET
Globus Medical reported first-quarter 2026 net sales of $759.9 million, up 27.0% from a year earlier, and GAAP net income of $124.3 million, up 64.7%. The company reaffirmed its full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and raised its non-GAAP diluted EPS guidance to $4.70 to $4.80 from $4.40 to $4.50.
- Q1 2026 net sales were $759.9 million, up 27.0%; base business excluding Nevro rose 13.2% to $677.2 million
- GAAP diluted EPS was $0.90 versus $0.54 a year earlier; non-GAAP diluted EPS was $1.12 versus $0.68
- Full-year 2026 revenue guidance reaffirmed at $3.18 billion to $3.22 billion
- Non-GAAP diluted EPS guidance raised to $4.70 to $4.80 from $4.40 to $4.50
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
